PRMT5 deficiency in myeloid cells reprograms macrophages to enhance antitumor immunity and synergizes with anti-PD-L1 therapy
These findings uncover a crucial role for PRMT5 in macrophage biology and suggest that targeting PRMT5 in myeloid cells offers a promising new approach for cancer immunotherapy. The combination of PRMT5 inhibition with anti-PD-L1 therapy may provide a potent strategy to reprogram the TME and enhance antitumor immune responses.
Authors
- Jian Cao (ORCID: https://orcid.org/0000-0003-3424-6802)
- Shiyu Chen (ORCID: https://orcid.org/0009-0002-1309-0175)
- Z Chen
- Bingqian Zhou
- Yongyu Chen (ORCID: https://orcid.org/0009-0004-3908-2063)
- Lisong Shen (ORCID: https://orcid.org/0000-0002-6647-4749)
- Yingxia Zheng
- Yan Huang
Institutions
- Rutgers, The State University of New Jersey (US)
- Shanghai Jiao Tong University (CN)
- XinHua Hospital (CN)
- Johnson University (US)
- Beijing Academy of Artificial Intelligence (CN)
- Rutgers Cancer Institute (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/jitc-2024-011299
- Citations
- 4
- Primary Topic
- Cancer-related gene regulation
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China